Cizzle Biotechnology Holdings PLC (LSE:CIZ) said it has secured patent approval in Canada for its CIZ1B biomarker, strengthening protection for its proprietary two-step blood test for the early detection of lung cancer. The newly granted patent enhances the commercial position of its licensing partner, Cizzle Bio Inc, as rollout efforts continue across North America, while also supporting the company’s wider strategy to build a globally protected intellectual property portfolio alongside anticipated U.S. approvals.
The reinforced patent coverage underpins Cizzle’s ambition to align its technology with national early-detection frameworks, including the NHS cancer plan, and is intended to support deeper engagement with clinical laboratories and hospital networks. Management said the expanded intellectual property footprint is central to safeguarding shareholder value by ensuring exclusive use of the CIZ1B technology as commercial partnerships scale in key markets.
Despite the strategic progress on intellectual property, the company’s overall outlook remains constrained by financial factors. Cizzle continues to operate on a pre-revenue basis, with ongoing losses, sustained cash outflows and a significantly reduced equity base weighing on sentiment. Technical indicators also suggest muted share price momentum, while valuation metrics offer limited support due to negative earnings and the absence of dividend visibility.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a biotechnology company focused on the development of non-invasive, blood-based diagnostics for the early detection of lung cancer. Its work centres on the CIZ1B biomarker, with the technology licensed to partners across North America, the Caribbean and other regions, while the group also targets expansion aligned with NHS initiatives in the UK and Europe.
Leave a Reply